Malaria Threats Map

Malaria Policy Advisory Committee Meeting

Geneva, Switzerland

18 October 2017

1. Scope

2. Progress

3. Status

4. Data overview

5. Demonstration

6. Plans

Overview

Scope

Vector insecticide resistance (bioassays, mechanisms) hrp2/3 gene deletions (single and mixed) Antimalarial drug efficacy and drug resistance (therapeutic efficacy studies (TES), molecular markers)

Biological challenges to malaria control and elimination

Progress

• Extra data ie. 2016/2017

• Significant refinement of:

• Data filters

• Dynamic legends

• Symbols ie. toggle for country/site data

• Popup content ie. text, tables and figures

• Geographies navigator

• Formulated explanatory text

• Translated all content ie. French, Spanish

Updates since MPAC March 2017

Status

• 98% completed

• Pending: minor updates to functionality and aesthetics

• Launch: anticipated by end October 2017

As of 18 October 2017

Data overview

Bioassays (standard only) discriminating concentration intensity concentration

Mechanisms (biochemical, molecular, synergist-insecticide assays) metabolic - mono oxygenases, esterases, GSTs target-site mutations - kdr , Ace1R

Vector insecticide resistance 1949 – 2017

bioassays (all), mechanisms 91 countries = 29,137 tests

GMP Databases

hrp2/3 gene deletions 1996 – 2017

suspected, confirmed 26 countries = 131 survey areas

Drug efficacy & drug resistance 2004 – 2017

TES results, molecular markers 78 countries = 2,133 studies

Vector insecticide resistance 2010 – 2017

bioassays (standard), mechanisms 83 countries = 18,712 tests

hrp2/3 gene deletions 1998 – 2017 confirmed

24 countries = 125 survey areas

Drug efficacy & drug resistance 2010 – 2017

TES results, molecular markers 71 countries = 1,006 studies

Malaria Threats Map

Data overview

Type of deletion pfhrp2 pfhrp2 and 3

Survey type Cross sectional Convenience/screening Case report DHS

Clinical status symptomatic asymptomatic mixed or unknown

Vector insecticide resistance 1949 – 2017

bioassays (all), mechanisms 91 countries = 29,137 tests

GMP Databases

hrp2/3 gene deletions 1996 – 2017

suspected, confirmed 26 countries = 131 survey areas

Drug efficacy & drug resistance 2004 – 2017

TES results, molecular markers 78 countries = 2,133 studies

Vector insecticide resistance 2010 – 2017

bioassays (standard), mechanisms 83 countries = 18,712 tests

hrp2/3 gene deletions 1998 – 2017 confirmed

24 countries = 125 survey areas

Drug efficacy & drug resistance 2010 – 2017

TES results, molecular markers 71 countries = 1,006 studies

Malaria Threats Map

Across surveys, the criteria for selecting samples to test for pfhrp2/3 deletions varies. Percentage of samples tested with deletions is presented

Data overview

Therapeutic efficacy studies P. falciparum P. vivax

Molecular marker studies K13 Pfcrt (next version)

Vector insecticide resistance 1949 – 2017

bioassays (all), mechanisms 91 countries = 29,137 tests

GMP Databases

hrp2/3 gene deletions 1996 – 2017

suspected, confirmed 26 countries = 131 survey areas

Drug efficacy & drug resistance 2004 – 2017

TES results, molecular markers 78 countries = 2,133 studies

Vector insecticide resistance 2010 – 2017

bioassays (standard), mechanisms 83 countries = 18,712 tests

hrp2/3 gene deletions 1998 – 2017 confirmed

24 countries = 125 survey areas

Drug efficacy & drug resistance 2010 – 2017

TES results, molecular markers 71 countries = 1,006 studies

Malaria Threats Map

Live demonstration

Live demonstration

Live demonstration

Live demonstration

Mobile compatibility: pending

Interim

• Finalise pending updates

• Shift to WHO server and launch

• Beta test and address arising issues (eg. bugs)

• Conduct consultations to define priorities for optimising / expanding

Phase II development

Potential options:

• Regional symbols and pop-ups (to compare across countries)

• Data upload / download

• Automated summary report

• Print functionality

• Mobile compatibility

Plans

Thank you

For further information:

• The URL to the Malaria Threats Map beta application will be circulated widely upon launch

Tessa Knox: knoxt@who.int

Jane Cunningham: cunninghamj@who.int

Amy Barrette: barrettea@who.int